查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884069

重組凝血酶市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Recombinant Thrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 請詢問到貨日

價格

重組凝血酶市場成長驅動因子

全球重組凝血酶市場正經歷穩定成長，其成長動力主要來自外科手術數量的增加、人口老化以及安全有效的止血劑的日益普及。根據本報告，預計該市場規模將在 2024 年達到 4.398 億美元，2025 年將增長至 4.583 億美元，並在 2032 年達到 6.551 億美元，預測期內複合年增長率 (CAGR) 為 5.2%。北美地區憑藉其先進的醫療保健基礎設施和需要外科手術幹預的慢性疾病高發生率，在 2024 年佔市場主導地位，市場佔有率達 42.11%。

以重組DNA技術生產的重組凝血酶與牛源或人源凝血酶相比，安全性較高，免疫原性、病毒性和過敏反應的風險顯著降低。隨著生物技術的進步以及醫療機構對高純度止血劑日益重視，重組凝血酶在心臟病學、神經病學、骨科、肝病學和普通外科等專科領域的臨床應用價值不斷提升。

市場動態

推動因素

手術量增加

包括心血管疾病、骨科疾病和神經系統疾病在內的慢性疾病的快速增長，導致全球手術量激增。吸煙、壓力和缺乏運動等生活方式風險進一步加重了疾病負擔。因此，醫療機構擴大採用重組凝血酶進行精準的術中出血管理。

例如，德國預計2023年將進行168,841例心臟手術，比2022年增長4.1%，這表明對可靠的止血劑的需求不斷增長。

限制因子

重組凝血酶成本高

複雜的生物技術生產流程顯著增加了生產成本，使得重組凝血酶比傳統凝血酶產品更昂貴。例如，20,000 IU的Recotron價格約為377.23美元，這限制了其在低收入國家和醫療資源匱乏地區的應用。此外，儘管其安全性極佳，但有限的醫保報銷進一步阻礙了其市場滲透。

機會

人源與牛源凝血酶的副作用創造了市場機會

傳統的凝血酶產品，例如牛源凝血酶 THROMBIN-JMI，與多種不良事件相關，包括免疫反應、出血併發症和血栓栓塞。重組凝血酶消除了病原體傳播的風險，並顯著降低了抗體的形成。

目前，Recothrom 是唯一獲得 FDA 批准的重組凝血酶產品，這為市場參與者開發新配方和擴展產品線提供了巨大的機會。

挑戰

複雜的生產製程

重組凝血酶的生產需要精確的基因克隆、可控制的細胞培養系統和先進的純化技術。批次缺陷、嚴格的合規要求以及可擴展性挑戰推高了營運成本，阻礙了市場的快速擴張。

市場趨勢

合併止血劑的研發加速

各大公司正加速研發聯合產品，以增強術中止血效果。

2023年4月，百特公司推出了Flosil + Recotron，這是全球首款含有重組凝血酶的可流動止血劑，標誌著外科止血技術領域的重大突破。

市場區隔分析

依應用領域

2024年，治療領域推動了市場成長，這主要得益於心血管外科、神經外科、骨科和肝臟外科的廣泛應用。光是在美國，2024年就進行了超過一百萬例經導管心血管手術，所有這些手術都需要有效的止血。

重組凝血酶在研究領域也佔了相當大的佔有率，這得益於其在融合蛋白裂解、分子生物學研究和高純度實驗室應用中的廣泛用途。

依最終使用者劃分

醫院和門診手術中心 (ASC) 因其手術量大而成為市場的主要推動力。例如，2024 年美國進行了超過 70 萬例膝關節置換手術。

由於重組蛋白在生物技術研究中的應用日益廣泛，研究機構也持續看到其應用範圍的擴大。

區域展望

北美（2024 年市場規模：1.852 億美元）

該地區憑藉較高的手術率、技術應用以及對安全止血劑的強烈認知，在市場中佔主導地位。美國在心血管和骨科手術領域佔市場領先地位。

歐洲

由於人口老化和創傷相關手術的增加，歐洲是第二大市場。德國、法國和英國在生物技術研發方面的進步也推動了市場的進一步擴張。

亞太地區

由於病患數量、手術量和研發投入的增加，預計亞太地區將實現最快的成長速度。

例如，阿斯特捷利康計劃在2025年投資25億美元在北京建立一個研發中心。

拉丁美洲、中東和非洲

成長的推動力在於醫療基礎設施的改善以及微創手術中心的日益普及，例如 Burjeel Holdings 的日間手術中心，該中心於 2024 年開業。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家和地區的監管環境
  • 市場技術進步
  • 主要產業趨勢（併購、合作、新產品發表等）

第五章：全球重組凝血酶市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依應用領域劃分
    • 治療
    • 研究
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 醫院及門診手術中心
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美重組凝血酶市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲重組凝血酶市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區重組凝血酶市場分析、洞察與預測 (2019-2032)

  • 依國家/地區
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳大利亞
    • 亞太其他地區

第九章 拉丁美洲重組凝血酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章 中東與非洲重組凝血酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 百特
    • 默克集團
    • Bio-Techne
    • AMSBIO
    • Enzyme Research Laboratories Ltd.
    • Proteintech Group, Inc.
Product Code: FBI113585

Growth Factors of recombinant thrombin Market

The global recombinant thrombin market is experiencing consistent growth driven by rising surgical volumes, an aging population, and increasing adoption of safe and efficient hemostatic agents. According to the report, the market size reached USD 439.8 million in 2024, is set to grow to USD 458.3 million in 2025, and is projected to attain USD 655.1 million by 2032, reflecting a CAGR of 5.2% during the forecast period. North America dominated the market in 2024 with a 42.11% share, supported by its advanced healthcare infrastructure and high prevalence of chronic conditions requiring surgical intervention.

Recombinant thrombin, produced using recombinant DNA technology, offers improved safety compared to bovine or human-derived thrombin due to significantly lower risks of immunogenic reactions, viral transmission, and allergic responses. As biotechnology advances and healthcare facilities increasingly prioritize high-purity hemostatic solutions, recombinant thrombin continues to gain clinical importance across cardiovascular, neurology, orthopedic, liver, and general surgery specialties.

Market Dynamics

Drivers

Increasing Number of Surgical Procedures

A surge in chronic diseases-such as cardiovascular disorders, orthopedic impairments, and neurological conditions-has led to a high number of surgical interventions globally. Lifestyle risks such as tobacco use, stress, and physical inactivity further contribute to disease burden. This has driven healthcare facilities to adopt recombinant thrombin for precise intraoperative bleeding control.

For example, Germany recorded 168,841 heart surgery procedures in 2023, a 4.1% increase from 2022, showcasing the growing need for reliable hemostatic agents.

Restraints

High Cost of Recombinant Thrombin

The complex biotechnological manufacturing process significantly increases production costs, making recombinant thrombin more expensive than traditional thrombin products. For instance, Recothrom 20,000 IU costs approximately USD 377.23, limiting its adoption in low-income nations or underfunded healthcare systems. Additionally, limited reimbursement support further restricts market penetration despite its superior safety profile.

Opportunities

Adverse Effects of Human and Bovine Thrombin Create Market Potential

Traditional thrombin products such as bovine-derived THROMBIN-JMI have been associated with adverse events including immune reactions, bleeding complications, and thromboembolic events. Recombinant thrombin eliminates risks of pathogen transmission and significantly reduces antibody formation.

Since only one FDA-approved recombinant thrombin (Recothrom) exists, market players have substantial opportunity to explore new formulations and expand product pipelines.

Challenges

Complex Manufacturing Process

Producing recombinant thrombin requires precise gene cloning, controlled cell culture systems, and high-level purification techniques. Batch failures, strict compliance needs, and challenges in scalability raise operational costs and hinder rapid market expansion.

Market Trends

Growing Development of Combination Hemostatic Products

Leading companies are increasingly developing combination products to enhance intraoperative bleeding control.

In April 2023, Baxter launched Floseal + Recothrom, the world's first active flowable hemostat integrating recombinant thrombin, representing a major advancement in surgical hemostasis.

Segmentation Analysis

By Application

The therapeutic segment dominated in 2024, driven by extensive use in cardiovascular, neurosurgical, orthopedic, and liver surgeries. In the U.S. alone, over 1.0 million transcatheter cardiovascular procedures were performed in 2024, each requiring efficient bleeding control.

The research segment also held a significant share, as recombinant thrombin is widely used for fusion protein cleavage, molecular biology studies, and high-purity experimental applications.

By End User

Hospitals and ambulatory surgical centers (ASCs) led the market due to high surgical volumes. As an example, over 700,000 knee replacement surgeries were conducted in the U.S. in 2024.

Research institutes continue to expand usage due to the increasing adoption of recombinant proteins in biotechnology research.

Regional Outlook

North America (2024 Value: USD 185.2 Million)

The region dominates the market due to high surgical procedure rates, technological adoption, and strong awareness about safe hemostats. The U.S. leads with significant cardiovascular and orthopedic surgery volumes.

Europe

Europe represents the second-largest market driven by its aging population and growing trauma-related surgeries. Biotechnology R&D advancements in Germany, France, and the U.K. further support market expansion.

Asia Pacific

Expected to grow at the fastest rate due to expanding patient pools, increased surgical volumes, and rising research investments.

For instance, AstraZeneca invested USD 2.5 billion in 2025 to establish an R&D center in Beijing.

Latin America & Middle East/Africa

Growth is fueled by improving healthcare infrastructure and rising availability of minimally invasive surgical centers, such as Burjeel Holdings' one-day surgery centers launched in 2024.

Conclusion

Growing surgical needs, improved safety profiles, and rising biotechnological advancements are set to expand the recombinant thrombin market from USD 439.8 million in 2024 to USD 655.1 million by 2032. With increasing demand for efficient and safe hemostatic agents, the market is positioned for stable, long-term global growth.

Segmentation By Application

  • Therapeutic
  • Research

By End User

  • Hospitals and ASCs
  • Research Institutes
  • Others

By Region

  • North America (By Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Application, End User, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, End User, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regolatory Scenarios, By Key Countries/Regions
  • 4.2. Technological Advancements in the Market
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals & ASCs
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals & ASCs
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. S.
    • 6.3.2. Canada

7. Europe Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals & ASCs
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals & ASCs
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Southeast Asia
    • 8.3.5. Australia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals & ASCs
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Application
    • 10.1.1. Therapeutic
    • 10.1.2. Research
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals & ASCs
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Baxter
      • 11.2.1.1. Overview
      • 11.2.1.2. Product Types
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck KGaA
      • 11.2.2.1. Overview
      • 11.2.2.2. Product Types
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bio-Techne
      • 11.2.3.1. Overview
      • 11.2.3.2. Product Types
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AMSBIO
      • 11.2.4.1. Overview
      • 11.2.4.2. Product Types
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Enzyme Research Laboratories Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product Types
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Proteintech Group, Inc
      • 11.2.6.1. Overview
      • 11.2.6.2. Product Types
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 2: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 3: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 4: North America Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 5: North America Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 6: North America Recombinant Thrombin Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 7: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 8: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 9: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 14: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 15: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 18: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Recombinant Thrombin Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Recombinant Thrombin Market Value Share (%), by Application, 2024 & 2032
  • Figure 3: Global Recombinant Thrombin Market Value Share (%), by End User, 2024 & 2032
  • Figure 4: Global Recombinant Thrombin Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 6: North America Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 7: North America Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 8: North America Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 9: North America Recombinant Thrombin Market Value (USD million), By Country, 2024 & 2032
  • Figure 10: North America Recombinant Thrombin Market Value Share (%), By Country, 2024
  • Figure 11: Europe Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 12: Europe Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 13: Europe Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: Europe Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 15: Europe Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 18: Asia Pacific Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 19: Asia Pacific Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Asia Pacific Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 21: Asia Pacific Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 24: Latin America Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 25: Latin America Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 26: Latin America Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 27: Latin America Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 30: Middle East & Africa Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 31: Middle East & Africa Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 32: Middle East & Africa Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 33: Middle East & Africa Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Recombinant Thrombin Market Share (%), By Company, 2024